1. Dosage
Proton pump inhibitors (PPIs) are FDA-approved for managing duodenal and gastric ulcers, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), hypersecretory conditions, and heartburn, preventing nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers, and eradicating Helicobacter pylori (as a component of combination therapy) [1-9].
Omeprazole/sodium bicarbonate combination therapy is FDA-approved for managing gastric and duodenal ulcer, EE, GERD, and upper gastrointestinal bleed risk reduction in critically ill patients [1,2,10].
Esomeprazole combined with naproxen is FDA-approved for use in osteoarthritis (OA), rheumatoid arthritis (RA), or ankylosing spondylitis (AS) in patients at greater risk for developing NSAID-induced gastric ulcers [1,2,11].